Biotherapy Services are very pleased to announce our RAPID-1 (Diabetic Foot Ulcer) trial has enrolled and dosed its first patient following suspension of the trial due to the Covid-19 pandemic restrictions. This could only have been made possible with the collaborative approach from the PHARMExcel team, who took over the trial management in early 2020. This makes RAPID-1 one of the first non-covid trials to re-open since March 2020 following the national lockdowns. In the 12 month downtime, we have extended the trial to now support multiple sites, care settings and incorporated adapted measures to minimise the risks of Covid-19 to this vulnerable patient group. We have also welcomed the addition of IgniteData, a specialist patient finding company to help us address the inherent health inequalities Diabetic patients experience. We are now back on track and could only have achieved this with the supportive can do/how can we do it attitude of the PHARMExcel & IgniteData teams, which closely match our own Company values and ethos. We hope that this new treatment will benefit those suffering from DFUs by using the patient’s own blood, thus harnessing the body’s own ability to heal.